Table 4 Variables associated with OS in patients with clinical benefit
IMDC risk score | N | Median OS (in months) | Univariable analysis | Multivariable analysis | ||
|---|---|---|---|---|---|---|
HR (95% CI) | p-value | HR (95% CI) | p-value | |||
Age | 52 | 28.73 | 1.00 (0.93, 1.08) | 0.94 | Â | Â |
BMI group | ||||||
 Normal | 14 | 28.73 | 1.00 | Ref | 1.00 | Ref |
 Overweight | 25 | 30.67 | 0.19 (0.04, 1.01) | 0.05 | 0.15 (0.03, 0.86) | 0.03 |
 Obese | 13 | – | 0.25 (0.04, 1.41) | 0.12 | 0.19 (0.03, 1.11) | 0.07 |
Smoking history | ||||||
 No | 27 | 30.67 | 1.00 | Ref |  |  |
 Yes | 25 | 28.73 | 0.51 (0.14, 1.82) | 0.30 |  |  |
Nephrectomy | ||||||
 Total | 44 | 28.73 | Ref | Ref |  |  |
 Partial | 3 | – | – | 0.99 |  |  |
 None | 5 | – | 1.25 (0.15, 10.16) | 0.84 |  |  |
ICI line of treatment | ||||||
 First line | 5 | – | – | 0.99 |  |  |
 Second line | 23 | 30.67 | 1.00 | Ref |  |  |
 Third line | 17 | – | 0.86 (0.21, 3.64) | 0.84 |  |  |
 Fourth line | 5 | – | 0.88 (0.10, 7.67) | 0.91 |  |  |
 > 4 prior treatments | 2 | 28.73 | 1.55 (0.15, 15.97) | 0.71 |  |  |
ECOG PS at start of immunotherapy | ||||||
 0 | 19 | 30.67 | 1.00 | Ref |  |  |
 1 or 2 or 3 | 32 | 28.73 | 5.96 (0.72, 49.62) | 0.10 |  |  |
 Missing | 1 | – | – | – |  |  |
IMDC risk score | ||||||
 Favorable | 13 | 30.67 | 1.00 | Ref |  |  |
 Intermediate | 32 | 28.73 | 1.02 (0.25, 4.13) | 0.97 |  |  |
 Poor | 3 | – | – | 0.99 |  |  |
Occurrence of irAE | ||||||
 No | 33 | 30.67 | 1.00 | Ref |  |  |
 Yes | 19 | 28.73 | 0.80 (0.20, 3.19) | 0.75 |  |  |
Prior brain mets | ||||||
 No | 47 | 30.67 | 1.00 | Ref | 1.00 | Ref |
 Yes | 5 | 15.75 | 6.49 (1.53, 27.56) | 0.01 | 9.41 (1.94, 45.71) | 0.005 |